Stem cell transplant study probes hidden toll on smell and taste
NCT ID NCT06003660
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 70 people receiving a stem cell transplant for leukemia or myelodysplastic syndrome. Researchers will test their sense of smell, taste, mouth pain, and saliva production before and after the transplant. The goal is to understand how the treatment changes these functions and brain connections, not to test a new drug or therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients receiving myeloablative conditioning for a first-time allo-HSCT and diagnosed with either a leukemia or a myelodysplastic syndrome.
- Ages
-
30 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: • patients receiving myeloablative conditioning for a first-time allo-HSCT and diagnosed with either a leukemia or a myelodysplastic syndrome Exclusion Criteria: * disorders affecting the oral cavity including poor tooth-status * those using drugs affecting the gustatory/olfactory functions * those with brain disorders * those who have a chronic disorder affecting the immune system, have cancer or who are pregnant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic stem cell transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Oslo
RECRUITINGOslo, Oslo, 0254, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Platelet-Boosting drug help control a rare bone marrow disorder?
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Can a drug and donor cells stop leukemia from returning after transplant?
- Can a bone drug plus immune signal stop blood cancer from returning after transplant?
- Can a Nine-Week group program help blood cancer patients grow through trauma?
- Two-Drug combo aims to push CLL into deep remission